Podcast #19 · 17 Jun 2025
Intravesical Therapies for Intermediate Risk Bladder Cancer
- Medical Oncology
- Transurethral Resection of Bladder Tumor (TURBT)
- Urologic Oncology
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- In-Office Procedures
- Intravesical Therapy
- Bladder Cancer
With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.
This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025.